Overview

Trichomonas Vaginalis Recurrence Among HIV+ Women

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tulane University Health Sciences Center
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Metronidazole
Criteria
Inclusion Criteria:

- Female

- 18 years or older

- HIV-positive

- TV positive by either wet preparation or culture

- ability to refrain from all alcohol use for 24 hours before and after taking oral
metronidazole

- willing to take metronidazole treatment

Exclusion Criteria:

- pregnant

- incarcerated

- previously enrolled

- currently taking disulfiram

- alcoholism or known liver damage

- medical contraindications to metronidazole

- treated with metronidazole within the previous 14 days

- requires treatment for B.V. per Amsel's criteria